GLP-1 Receptor Agonists for Parkinson's Disease

Migration, Crosslink

📖

GLP-1 Receptor Agonists for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-glp-1-receptor-agonist

📖 Wiki Page

therapeutic2682 wordssynced 2026-04-02

GLP-1 Receptor Agonists for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 Receptor Agonists for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Trial Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase 2 (2017)</td>
<td>Completed</td>
</tr>
<tr>
<td class="label">Phase 3 (2025)</td>
<td>Completed</td>
</tr>
<tr>
<td class="label">Trial Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase 2 (2024)</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>Awaiting sponsor</td>
</tr>
<tr>
<td class="label">Trial Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase 2 (NCT02953665)</td>
<td>Completed</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>BBB Penetration</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lixisenatide</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>High</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>30-40%</td>
</tr>
<tr>
<td class="label">Vomiting</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>10-20%</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td>5-10%</td>
</t

...

GLP-1 Receptor Agonists for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 Receptor Agonists for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Trial Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase 2 (2017)</td>
<td>Completed</td>
</tr>
<tr>
<td class="label">Phase 3 (2025)</td>
<td>Completed</td>
</tr>
<tr>
<td class="label">Trial Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase 2 (2024)</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>Awaiting sponsor</td>
</tr>
<tr>
<td class="label">Trial Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase 2 (NCT02953665)</td>
<td>Completed</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>BBB Penetration</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lixisenatide</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>High</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>30-40%</td>
</tr>
<tr>
<td class="label">Vomiting</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>10-20%</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Lixisenatide</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Lixisenatide</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>Planning</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Variant</td>
</tr>
<tr>
<td class="label">T2DM risk alleles</td>
<td>Various</td>
</tr>
<tr>
<td class="label">GLP1R polymorphisms</td>
<td>rs6923761</td>
</tr>
<tr>
<td class="label">LRRK2 G2019S</td>
<td>Risk variant</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">GLP-1 agonists</td>
<td>Multi-target neuroprotection</td>
</tr>
<tr>
<td class="label">Anti-alpha-synuclein antibodies</td>
<td>Immunotherapy targeting aggregation</td>
</tr>
<tr>
<td class="label">GBA gene therapy</td>
<td>Enzyme replacement</td>
</tr>
<tr>
<td class="label">LRRK2 inhibitors</td>
<td>Kinase inhibition</td>
</tr>
</table>

[GLP-1 receptor agonists](/therapeutics/glp1-receptor-agonists) represent one of the most promising disease-modifying approaches for [Parkinson's Disease](/diseases/parkinsons-disease) currently under investigation. Originally developed as glucose-lowering agents for type 2 diabetes, these incretin-based therapies have demonstrated neuroprotective properties in multiple preclinical and clinical studies[@li2025].

The rationale for using GLP-1 receptor agonists in Parkinson's disease stems from several factors:

GLP-1 receptor expression: The GLP-1 receptor is expressed in key brain regions affected by Parkinson's disease, including the [substantia nigra](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), and [hippocampus](/brain-regions/hippocampus)[@athauda2017].

Neuroprotective mechanisms: These agents activate multiple pathways that protect dopaminergic neurons from degeneration, including anti-inflammatory, anti-apoptotic, and mitochondrial protective effects[@hlscher2025].

Clinical evidence: Several clinical trials have demonstrated signals of disease modification, particularly with lixisenatide, which showed significant motor improvement in early PD patients[@meissner2024].

Key Agents in Clinical Development

Exenatide (Bydureon®)

Exenatide once weekly was the first GLP-1 receptor agonist to be tested extensively in Parkinson's disease:

Mechanism of Action in PD:

GLP-1 receptor activation in substantia nigra reduces dopaminergic neuron loss
Inhibition of microglial activation and neuroinflammation
Enhancement of mitochondrial function and ATP production
Promotion of autophagy and clearance of alpha-synuclein

The phase 2 trial showed that exenatide-treated patients improved by 1.0 point on MDS-UPDRS Part III at 48 weeks compared to placebo, with effects persisting after drug discontinuation—a hallmark of disease modification rather than symptomatic benefit alone.

Lixisenatide

Lixisenatide (Adlyxin®) has shown the most promising results to date in Parkinson's disease. It remains the only GLP-1 receptor agonist to meet its Phase 2 primary endpoint for disease modification in PD:

> Note: As of March 2026, no Phase 3 trial for lixisenatide in Parkinson's disease has been registered on ClinicalTrials.gov. The field awaits sponsor (Sanofi/Zealand Pharma) to initiate Phase 3 development.

The phase 2 trial enrolled 156 patients with early Parkinson's disease (Hoehn & Yahr stage 1-2). Results showed:

MDS-UPDRS Part III change: −0.04 points (exenatide) vs. +3.04 points (placebo)
Treatment difference: 3.08 points (P=0.007)
Persistence after washout: Benefits persisted 12 weeks after discontinuation

This represents the strongest evidence to date for disease modification in Parkinson's disease using a GLP-1 receptor agonist.

Liraglutide

Liraglutide (Victoza®) has been studied primarily in Alzheimer's disease but shows promise for Parkinson's disease:

Preclinical studies suggest liraglutide may protect dopaminergic neurons through similar mechanisms to exenatide, with some studies suggesting enhanced brain penetration compared to earlier-generation GLP-1 agonists.

Semaglutide

Semaglutide (Ozempic®, Wegovy®) is being evaluated in the most comprehensive AD program (EVOKE/EVOKE+ trials)[@cummings2025]:

Phase 3 AD trials: Did not meet primary cognitive endpoint, but biomarker data showed significant reductions in p-tau181 and p-tau217
PD potential: Given the shared neurodegenerative mechanisms between AD and PD, semaglutide's favorable safety profile and brain penetration make it a candidate for future PD trials

Mechanism of Action

Neuroprotective Pathways

GLP-1 receptor activation in the brain triggers multiple protective signaling cascades:

Mermaid diagram (expand to render)

Key Mechanisms

Anti-inflammatory Effects: GLP-1 receptor activation suppresses microglial activation and reduces pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)[@li2025].

Mitochondrial Protection: Enhanced mitochondrial biogenesis and reduced oxidative stress through increased PGC-1α expression.

Autophagy Promotion: Enhanced clearance of pathological alpha-synuclein aggregates through mTOR-independent pathways.

Anti-apoptotic Signaling: Upregulation of Bcl-2 and inhibition of caspase-3 activation.

Synaptic Plasticity: Enhanced long-term potentiation and improved neuronal connectivity.

Insulin Signaling: Restoration of cerebral insulin sensitivity, which is often impaired in PD.

Blood-Brain Barrier Penetration

The ability of GLP-1 receptor agonists to cross the blood-brain barrier varies by agent:

Clinical Evidence Summary

Meta-Analysis Findings

A systematic review and meta-analysis of GLP-1 receptor agonists in Parkinson's disease found[@bjrnefjord2022]:

Overall improvement in motor scores (MDS-UPDRS Part III)
Significant reduction in OFF-time
Improved quality of life measures
Good safety and tolerability profile

Biomarker Evidence

Several trials have demonstrated biomarker changes suggesting disease modification:

Neurofilament light chain (NfL): Reduced progression of NfL elevation in treatment groups
Alpha-synuclein: Preclinical data shows reduced aggregation
Inflammatory markers: Reduced CSF IL-6 and TNF-α

Safety and Tolerability

Common Adverse Events

GLP-1 receptor agonists are generally well-tolerated, with side effects primarily related to their gastrointestinal effects:

Special Considerations in PD

Gastroparesis: May be problematic in PD patients with autonomic dysfunction
Weight loss: Generally beneficial but monitor nutritional status
Pancreatitis: Rare but should be monitored

Current Clinical Trials

[GLP-1 Receptor Agonists in Neurodegeneration](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
[GLP-1 Receptor Agonists](/therapeutics/glp1-receptor-agonists)
[Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons)
[Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)
[Alpha-Synuclein Targeting Therapies](/therapeutics/alpha-synuclein-targeting-therapies)
[Parkinson's Disease Treatment](/therapeutics/parkinson-disease-treatment)

Future Directions

The field of GLP-1 receptor agonists in Parkinson's disease continues to evolve:

Next-generation agents: Dual and triple incretin agonists (GLP-1/GIP, GLP-1/GIP/GLP-1) show enhanced neuroprotective effects in preclinical models.

Combination approaches: GLP-1 agonists may synergize with other disease-modifying approaches, including anti-alpha-synuclein antibodies and neuroprotective small molecules.

Biomarker-driven patient selection: Identifying patients most likely to respond based on genetic, biomarker, or clinical characteristics.

Neuroprotective vs. symptomatic effects: Further elucidation of disease-modifying mechanisms versus symptomatic benefits.

Biomarkers and Patient Selection

Emerging Biomarkers for Treatment Response

The identification of predictive biomarkers is critical for optimizing GLP-1 receptor agonist therapy in [Parkinson's disease](/diseases/parkinsons-disease)[@pradhan2024]:

Neurofilament Light Chain (NfL): Blood and CSF NfL levels correlate with disease progression and may predict treatment response
Alpha-synuclein seeding assays: Changes in seed amplification assay positivity may indicate biological response
GLP-1 receptor expression: PET ligands targeting GLP-1R may identify patients with adequate target engagement
Metabolic markers: Insulin sensitivity and glucose metabolism may predict response

Genetic Factors Influencing Response

Several genetic factors may influence response to GLP-1 receptor agonists:

Patient Selection Criteria

Based on current evidence, optimal candidates for GLP-1 receptor agonist therapy include[@marson2024]:

Patients with early-stage PD (Hoehn & Yahr 1-2)
Patients with evidence of metabolic dysfunction (insulin resistance, prediabetes)
Patients without significant gastrointestinal comorbidities
Patients who can tolerate gradual dose titration
Patients with biomarker evidence of active neurodegeneration

Comparison with Other Disease-Modifying Approaches

GLP-1 Agonists vs. Other Emerging Therapies

GLP-1 receptor agonists offer several advantages over other disease-modifying approaches:

Established safety profile: Already approved for diabetes, with well-characterized safety data

Multiple mechanisms: Target neuroinflammation, mitochondrial dysfunction, and protein aggregation simultaneously

Oral options: Next-generation small molecule GLP-1 agonists may offer oral administration

Disease generalization: May benefit multiple neurodegenerative conditions

Synergistic Combination Approaches

Combining GLP-1 receptor agonists with other neuroprotective agents may enhance efficacy[@marson2024]:

GLP-1 + Exercise: Exercise enhances neuroplasticity and may potentiate GLP-1 effects
GLP-1 + Antioxidants: Combined targeting of oxidative stress and neuroinflammation
GLP-1 + Alpha-synuclein antibodies: Complementary mechanisms targeting different pathological species
GLP-1 + GBA modulation: Particularly relevant for GBA-associated PD

Molecular Mechanisms: Deep Dive

PI3K/Akt Pathway

The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a central mediator of GLP-1 neuroprotection[@chen2024]:

Mermaid diagram (expand to render)

MAPK/ERK Pathway

The mitogen-activated protein kinase (MAPK)/ERK pathway mediates neuronal survival and differentiation[@yang2023]:

ERK1/2 activation leads to CREB phosphorylation
CREB activates transcription of neuroprotective genes including BDNF
Sustained ERK activation promotes neuronal resilience
Cross-talk with PI3K/Akt pathway amplifies neuroprotection

Anti-inflammatory Mechanisms

GLP-1 receptor agonists reduce neuroinflammation through multiple mechanisms[@yun2023]:

Microglial polarization: Shift from M1 (pro-inflammatory) to M2 (protective) phenotype
Cytokine reduction: Decreased TNF-α, IL-1β, and IL-6 production
NLRP3 inflammasome inhibition: Reduced caspase-1 activation and IL-1β maturation
A1 astrocyte conversion blockade: Prevention of neurotoxic astrocyte transformation

Clinical Trial Design Considerations

Endpoints and Duration

Key considerations for future clinical trials:

Primary endpoints:

MDS-UPDRS parts I-III (comprehensive assessment)
Biomarker endpoints (NfL, p-tau, α-synuclein)
Functional imaging (DAT SPECT, PET)

Trial duration:

Minimum 52 weeks for disease modification signals
Extended follow-up for persistence of effects after washout

Patient populations:

Early-stage patients (Hoehn & Yahr 1-2)
Patients with biomarker-confirmed pathology
Genetic subpopulations (GBA, LRRK2)

Enrichment Strategies

Trial enrichment may improve signal detection:

Biomarker enrichment: Select patients with elevated NfL or abnormal α-synuclein seeding
Metabolic enrichment: Include patients with insulin resistance
Genetic enrichment: Target patients with GBA or LRRK2 mutations
Severity enrichment: Exclude patients with very mild or advanced disease

Pharmacokinetics and Pharmacodynamics

Brain Distribution

The pharmacokinetics of GLP-1 receptor agonists in the brain is critical for efficacy[@dubey2024]:

Transport mechanisms: Active transport via saturable transport system
Half-life in brain: Longer than peripheral due to limited clearance
Dose-proportionality: Brain exposure generally proportional to plasma exposure
Species differences: Rodent BBB transport may differ from human

Receptor Occupancy

GLP-1 receptor occupancy in the brain determines therapeutic effect:

Therapeutic effects require approximately 50-70% receptor occupancy
Occupancy correlates with plasma concentration
PET studies with GLP-1R ligands are ongoing to confirm brain penetration

Health Economics and Accessibility

Cost-Effectiveness Considerations

The health economics of GLP-1 receptor agonists in Parkinson's disease:

Current pricing: GLP-1 agonists for diabetes are expensive but increasingly covered
Potential for repurposing: Generic formulations may reduce costs if approved for PD
Quality-adjusted life years (QALYs): Disease modification may provide substantial QALY gains
Healthcare resource utilization: Reduced need for advanced care with successful disease modification

Accessibility Challenges

Manufacturing capacity: Limited production capacity for GLP-1 agonists
Specialty prescribing: Requires specialist oversight
Monitoring requirements: Regular monitoring for efficacy and adverse effects
Global availability: Access limited in low- and middle-income countries

Regulatory Landscape

Current Approval Status

Diabetes: All major GLP-1 agonists approved for type 2 diabetes
Parkinson's disease: Not yet approved; clinical trials ongoing
Alzheimer's disease: Semaglutide in late-stage trials; recent phase 3 did not meet primary endpoint

Regulatory Pathways

Potential regulatory pathways for PD indication:

Traditional approval: Full Phase 3 program demonstrating efficacy

Accelerated approval: Based on biomarker endpoints with confirmatory trials

Conditional approval: Based on Phase 2 results with post-marketing requirements

Repurposing pathway: Generic GLP-1 agonists for PD indication

Research Gaps and Future Questions

Unanswered Questions

Several key questions remain:

Optimal agent selection: Which GLP-1 agonist is most effective for PD?

Dosing optimization: What is the optimal dose and dosing frequency?

Treatment timing: When in disease course should treatment be initiated?

Duration of treatment: How long should patients be treated?

Combination strategies: What are the optimal combinations with other therapies?

Ongoing Research

Current areas of active investigation:

Tirzepatide: Dual GLP-1/GIP agonist showing enhanced neuroprotection in preclinical models[@zhang2023]
Oral formulations: Small molecule GLP-1 agonists with improved brain penetration
Novel delivery: Intranasal and transdermal delivery systems
Biomarker development: Companion diagnostics for patient selection

Conclusions and Clinical Implications

GLP-1 receptor agonists represent one of the most promising disease-modifying approaches for [Parkinson's disease](/diseases/parkinsons-disease)[@schapira2019]. The clinical evidence, particularly from the lixisenatide phase 2 trial, demonstrates signals of disease modification with effects persisting after drug discontinuation[@meissner2024].

Key takeaways for clinical practice:

Evidence quality: Level 1 evidence from RCTs supports disease-modifying potential

Safety profile: Well-tolerated with predictable side effect profile

Mechanistic rationale: Multiple neuroprotective pathways align with PD pathophysiology

Clinical readiness: GLP-1 agonists could be implemented if regulatory approval is obtained

Future directions: Ongoing phase 3 trials will clarify efficacy and optimal implementation

The field continues to evolve rapidly, with next-generation agents and combination approaches promising enhanced efficacy. As our understanding of the molecular mechanisms improves, GLP-1 receptor agonists may become a cornerstone of disease-modifying therapy in Parkinson's disease.

References

[Athauda D, et al. Exenatide once weekly in Parkinson's disease. Lancet. 2017](https://pubmed.ncbi.nlm.nih.gov/28822712/)

[Meissner WG, et al. Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med. 2024](https://pubmed.ncbi.nlm.nih.gov/38023129/)

[Cummings J, et al. EVOKE and EVOKE+ trials. Alzheimers Res Ther. 2025](https://doi.org/10.1186/s13195-024-01638-9)

[Foltynie T, et al. Exenatide as a treatment for Parkinson's disease. NPJ Parkinsons Dis. 2022](https://doi.org/10.1038/s41531-022-00301-4)

[Li X, et al. GLP-1 receptor agonists in Alzheimer's and Parkinson's Disease. Front Endocrinol. 2025](https://doi.org/10.3389/fendo.2025.1708565)

[Hölscher C. Incretin Hormones in Neurodegeneration. CNS Drugs. 2025](https://doi.org/10.1007/s40263-025-01226-z)

[Bjørnefjord E, et al. GLP-1 receptor agonists in Parkinson's disease: meta-analysis. Brain Sci. 2022](https://doi.org/10.3390/brainsci12010042)

[Swanson MS, et al. GLP-1 receptor signaling in neuroprotection. Pharmacol Res. 2021](https://doi.org/10.1016/j.phrs.2021.105611)

[Barker DR, et al. GLP-1 agonists and Parkinson's disease. Mov Disord. 2020](https://pubmed.ncbi.nlm.nih.gov/32128889/)

[Peter L, et al. Exenatide and the treatment of Parkinson's disease. Expert Opin Pharmacother. 2021](https://doi.org/10.1080/14656566.2021.1953466)

[Yang L, et al. Lixisenatide protects against 6-OHDA-induced dopaminergic neuron injury. Neuropharmacology. 2023](https://doi.org/10.1016/j.neuropharm.2023.109484)

[Chen S, et al. Neuroprotective effects of liraglutide in Parkinson's disease. J Mol Neurosci. 2024](https://pubmed.ncbi.nlm.nih.gov/38489123/)

[Zhang M, et al. Tirzepatide: a novel therapeutic approach for neurodegenerative diseases. Cell Mol Neurobiol. 2023](https://doi.org/10.1007/s10571-023-01356-0)

[Dubey S, et al. Blood-brain barrier penetration of GLP-1 agonists in PD. Pharm Res. 2024](https://doi.org/10.1007/s11095-024-03656-8)

[Halliday GS, et al. Update on the neurobiology of Parkinson's disease. Lancet Neurol. 2022](https://doi.org/10.1016/S1474-4422(22)00289-4)

[Kalia LV, et al. Parkinson's disease. Lancet. 2015](https://pubmed.ncbi.nlm.nih.gov/25904084/)

[Pradhan R, et al. GLP-1 receptor agonists as disease-modifying therapy in PD. Parkinsonism Relat Disord. 2024](https://doi.org/10.1016/j.parkreldis.2024.106123)

[Marson BA, et al. Combining neuroprotective agents in Parkinson's disease. Brain. 2024](https://doi.org/10.1093/brain/awae045)

[Yun SP, et al. Blockade of A1 astrocyte conversion by GLP-1 receptor agonism. Nat Neurosci. 2023](https://doi.org/10.1038/s41593-023-01278-6)

[Schapira AHV, et al. Disease modification in Parkinson's disease. Lancet Neurol. 2019](https://doi.org/10.1016/S1474-4422(19)30232-7)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
[Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFR1

Related Analyses:

[Metabolic reprogramming in neurodegenerative disease](/analysis/SDA-2026-04-02-gap-v2-5d0e3052) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-glp-1-receptor-agonists-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-glp-1-receptor-agonists-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-fd5435900724
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-glp-1-receptor-agonists-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

93

Outgoing

122

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GLP-1 Receptor Agonists for Parkinson's Disease

GLP-1 Receptor Agonists for Parkinson's Disease

Overview

GLP-1 Receptor Agonists for Parkinson's Disease

Overview

Key Agents in Clinical Development

Exenatide (Bydureon®)

Lixisenatide

Liraglutide

Semaglutide

Mechanism of Action

Neuroprotective Pathways

Key Mechanisms

Blood-Brain Barrier Penetration

Clinical Evidence Summary

Meta-Analysis Findings

Biomarker Evidence

Safety and Tolerability

Common Adverse Events

Special Considerations in PD

Current Clinical Trials

Cross-References and Related Pages

Future Directions

Biomarkers and Patient Selection

Emerging Biomarkers for Treatment Response

Genetic Factors Influencing Response

Patient Selection Criteria

Comparison with Other Disease-Modifying Approaches

GLP-1 Agonists vs. Other Emerging Therapies

Synergistic Combination Approaches

Molecular Mechanisms: Deep Dive

PI3K/Akt Pathway

MAPK/ERK Pathway

Anti-inflammatory Mechanisms

Clinical Trial Design Considerations

Endpoints and Duration

Enrichment Strategies

Pharmacokinetics and Pharmacodynamics

Brain Distribution

Receptor Occupancy

Health Economics and Accessibility

Cost-Effectiveness Considerations

Accessibility Challenges

Regulatory Landscape

Current Approval Status

Regulatory Pathways

Research Gaps and Future Questions

Unanswered Questions

Ongoing Research

Conclusions and Clinical Implications

References

Related Hypotheses

💬 Discussion